Unichem Laboratories share news, announcements and annual reports
NSE: UNICHEMLABBSE: 506690Pharmaceuticals & BiotechnologySmall Cap
Unichem Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1963 on BSE, Feb 2001 on NSE
Last close ₹483.75down ₹21.20 (4.20%)BSE ₹483.45
Share price at the NSE close on 30 Oct 2026. Previous close ₹504.95.
30 Oct: open ₹504.00, high ₹507.25, low ₹480.10
52-week range of traded prices to 30 Oct 2026
₹278.20Low, 30 Mar 2026₹687.20High, 9 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹3,406 Cr1,036th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 11.17
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹205 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 34.10
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.25
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹205 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.17
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 29,18136.7% delivered
Unichem Laboratories share news and announcements
714 announcements, routine notices left out, newest first. Page 10 of 15.
Apr 2016
Mar 2016
9 Mar · Corporate action
3 Mar · Board meeting
Jan 2016
Dec 2015
Oct 2015
Sep 2015
4 Sep · Legal
Clarification by Unichem Laboratories LimitedSubstantial increase in trading volumes have been observed in Unichem Laboratories Limited.The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company.Unichem Laboratories Limited has vide its letter inter-alia stated, "We wish to inform you that, to the best of our knowledge and understanding there is no price sensitive information which is pending dissemination by the company through the exchange to the investors / general public, which would have a bearing on the price/ volume behavior of the Company's Equity Shares."
Aug 2015
Jul 2015
15 Jul · Meeting
13 Jul · Disclosure of Voting Pattern - Clause 35A
Jun 2015
May 2015
15 May · Code of Conduct under SEBI(PIT) Reg., 2015
11 May · Dividend
Board of Directors of the Company at their meeting held on May 9, 2015, has recommend a final dividend of Rs . 2/-per share(100%)(Face Value of Rs. 2/- per share each) for the year ended March 31, 2015.(previous year total dividend of Rs. 8/- per share 400%)
Apr 2015
28 Apr · Board meeting
Interalia consider the following: i. Consider and approve the Audited Financial Results of the Company for the year ended March 31, 2015. ii. Recommendation of final Dividend if any.17 Apr · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Unichem Laboratories Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Unichem Laboratories Limited has vide its letter inter-alia stated," There is no price sensitive information which is pending for dissemination to the investors/general public, by the Company through the exchange which would have a bearing on the price/ volume behaviour of the Company's equity share."
Mar 2015
Feb 2015
Jan 2015
6 Jan · Board meeting
Inter-alia, to consider and take on record Un-Audited Results for the quarter and nine months ended December 31, 2014.
Dec 2014
12 Dec · Legal
Exchange had sought clarification from Unichem Laboratories Limited with respect to a news item captioned "Germany bans 80 generic drugs for insufficient trials". The Company has clarified that "We have been aware of the concerns with GVK Biosciences and have been cooperating with the European authorities, via our subsidiary Unichem Ireland. Of the products referred to, none of them are currently on sale in Germany from Unichem, therefore this action will have no material impact on the overall performance of Unichem Laboratories Limited".11 Dec · Legal
Exchange has sought clarification from Unichem Laboratories Limited with respect to recent news item captioned "Germany bans 80 generic drugs for insufficient trials". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.